Trial Profile

A clinical trial of VV-169 in the US in patients with multiple myeloma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Dec 2025 New trial record
23 Dec 2025 According to a Vyriad media release, company announced the closing of the $25M final tranche to its Series B financing, bringing the total Series B round to $85M. This additional funding supports the imminent first-in-human testing of VV169 in patients with relapsed or treatment-refractory multiple myeloma.
16 Dec 2025 According to a Vyriad media release, the company plans to begin a clinical trial in patients with multiple myeloma in the U.S. in 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com